Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)

European Journal of Nuclear Medicine

Volumn 21, Issue 7, 1994, Pages 640-646

  Camera, Luigi ^a   Kinuya, Seigo ^a   Garmestani, Kayhan ^b   Brechbiel, Martin W ^b   Wu, Chuanchu ^b   Pai, Lee H ^c   McMurry, Thomas J ^b   Gansow, Otto A ^b   Pastan, Ira ^c   Paik, Chang H ^a   Carrasquillo, Jorge A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biodistribution; Indium; Ligands; Monoclonal antibodies; Yttrium

Indexed keywords

ANTIBODY CONJUGATE; INDIUM 111; MONOCLONAL ANTIBODY; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD; BONE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; FEMALE; FEMUR; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; MOUSE; NONHUMAN;

ANIMAL; CHELATING AGENTS; COMPARATIVE STUDY; FEMALE; HETEROCYCLIC COMPOUNDS; INDIUM RADIOISOTOPES; ISOTHIOCYANATES; MICE; MICE, NUDE; PENTETIC ACID; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 0028285302     PISSN: 03406997     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/BF00285586     Document Type: Article

References (42)

1. Experimental radioimmunotherapy
2. Bismuth-212-labeled anti-Tac monoclonal antibody: α-particle emitting radionuclides as modalities for radioimmunotherapy
3. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice
4. Labeling monoclonal antibodies and F(ab')2 fragments with the α-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localization capacity
5. 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice
6. Monoclonal anti-bodybased therapy of a human tumor xenograft with a 177Iutetium-labeled immunoconjugate
7. Specific radioimmunotherapy using 90Y labeled monoclonal antibody in erythroleukemic mice
8. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen
9. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y labeled monoclonal antibody C017-A prepared by two bifunctional chelate techniques
10. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer
11. Generator-produced yttrium-90 for radioimmunotherapy
12. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies
13. Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody
14. The molecular structure of indium-DTPA
15. Comparative biodistribution of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts
16. Evaluation of indium-111- and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs
17. The deposition of rare earths in bone
18. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies
19. DTPA-coupled antibodies labeled with yttrium-90
20. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and toxicity
21. Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice
22. Comparison of five bifunctional chelate techniques for 90Y labeled monoclonal antibody C017-1A
23. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent
24. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates
25. Macrocyclic chelates of radiometals for diagnosis and therapy
26. Indium-111-and yttrium-90-labelled macrocyclic chelating agents
27. Investigation of N-linked macrocycles for 111In and 90Y labeling of proteins
28. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy
29. Evaluation of the serum stability and in vivo biodistribution of the 2-(p-isothiocyanatobenzyl)-cyclohexyl-DTPA (CHX-DTPA) and other ligands for yttrium-labeling of monoclonal antibodies
30. Convenient synthesis of bifunctional tetraaza macrocycles
31. Backbone-substituted DTPA ligands for 90Y radioimmunotherapy
32. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas
33. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin
34. Thermodynamic and kinetic studies of lanthanide complexes of 1,4,7,10,13-pentaazacyclopentadecane- N,N′,N″,N″′,N″″-pentaac etic acid and 1,4,7,10,13,16-hexaazacyclooctadecane- N,N′,N″,N″′, N″″,N″″′-hexaacetic acid
35. The stability in liver homogenates of indium-111 and yttrium-90 attached to antibody via two popular chelators
36. Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides